HOME >> MEDICINE >> NEWS
Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

Houston May 08, 2007 -- A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.

"Several clinical trials have confirmed the role of hormone therapy in recurrent ovarian cancer treatment, especially in patients with low-grade tumors," says review author Dr. Siqing Fu, an assistant professor of oncology at the University of Texas at Houston. "However, more research is needed to determine whether combining molecular-targeted therapy with hormonal therapy would be a more effective option."

Ovarian cancer is the deadliest of gynecological cancers; approximately 70 percent of patients are diagnosed in the later stages, when the 5-year survival rate drops below 25 percent. Traditional chemotherapy has proven to be generally ineffective against recurrent ovarian cancer, which has led researchers to investigate novel treatments.

"While a cure is unlikely, the goals of treatment are to control tumor-related symptoms and to improve or maintain quality of life," says Dr. Fu. "After surveying the latest research, combined molecular-targeted and hormonal therapy offers the greatest promise in achieving these goals and therefore deserves further investigation."


'"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
8-May-2007


Page: 1

Related medicine news :

1. Combined imaging approach may provide better identification of difficult-to-diagnose brain clots
2. Combined therapies may boost immune response and long-term protection against brain tumors
3. Combined liver-kidney transplant beneficial for patients with dual organ disease
4. Combined contrast enhanced MRI shows promise
5. Combined treatment cuts inflammatory cells in chronic obstructive pulmonary disease
6. Combined MRI and mammography more effective at detecting breast cancer in high-risk women
7. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
8. Bulimia may result from hormonal imbalance
9. 1 in 5 early-stage breast cancer patients may not follow hormonal therapy plan
10. Genomic tests improve prediction of breast cancer response to chemotherapy, hormonal therapy
11. Some nonhormonal therapies may offer relief from hot flashes, but with possible adverse effects

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
(Date:6/24/2016)... ... 2016 , ... Advanced Plastic Surgery Institute ( http://www.advancedplasticsurgeryinstitute.com ), ... official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns the practice, ... says the decision to support the pageant in an official capacity is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Southern Illinois ... are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy ... Gateway Convention Center in Collinsville. , They expect to treat approximately ...
(Date:6/24/2016)... Austin, TX (PRWEB) , ... June 24, 2016 , ... ... laude graduate, joins Evans Dermatology in the South Lamar location as of July 13, ... Texas Southwestern Medical School. As a medical student, she regularly volunteered at the Agape ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
Cached News: